Market Overview

UPDATE: Credit Suisse Initiates Regeneron Pharmaceutical at Outperform

Share:
Related REGN
Is It Closing Time At The Biotech Bar?
CVS Says New Cholesterol Drug Types Could Be Costly
Strong Dollar Hurts Profit Forecasts In Long Term (Seeking Alpha)

Credit Suisse initiales coverage on Regeneron Pharmaceutical (NASDAQ: REGN) with an Outperform rating and a $187 price target.

Credit Suisse said, "The primary value driver remains quarterly sales of Eylea. Proposed legislation regulating compounding pharmacies, a permanent J code in January and the launch in RVO could all help boost sales. Competitor data for Amgen's AMG145 (anti-PCSK9) and Ophthotech's Fovista have all recently been disclosed, and key clinical data for Regeneron are limited in the near term."

Regeneron Pharmaceutical closed at $144.90 on Monday.

Latest Ratings for REGN

DateFirmActionFromTo
Mar 2015Chardan CapitalInitiates Coverage onBuy
Feb 2015BernsteinInitiates Coverage onOutperform
Feb 2015Piper JaffrayDowngradesOverweightNeutral

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (REGN)

Around the Web, We're Loving...